Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc.

NVCT·NASDAQ

$9.67

+1.7%
HealthcareBiotechnology

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

At a Glance

Live Snapshot
Market Cap$256.50M
EPS-1.3200
P/E Ratio-7.33
Earnings Date08/04/2026

nvct

Income Before Tax

Last Annual Value

-26.44M

3-Year CAGR

-11%

5-Year CAGR

-384%

10-Year CAGR

-120%

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Competitors Analysis of Income Before Tax

NVCT · NASDAQ
CompanyIncome Before Tax
CAGR 3Y
CAGR 5Y
CAGR 10Y
-26.44M
N/AN/AN/A 
-63.24M
N/AN/AN/A
-104.87M
N/AN/AN/A
PEPG logo
PepGen Inc.
NASDAQ:PEPG
-89.61M
N/AN/AN/A
-22.23M
N/AN/AN/A
-34.77M
N/AN/AN/A
-19.36M
N/AN/AN/A
-13.73M
N/AN/AN/A
-45.88M
N/AN/AN/A
-40.95M
N/AN/AN/A
-124.02M
N/AN/AN/A
Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Fair Value Envelope

NVCT · NASDAQ

Our analysis suggests that NVCT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.67, this represents a potential HIDDEN relative to our calculated worth for Nuvectis Pharma, Inc..

Intrinsic Value
Current Price: $9.67